Doxifluridine (furtulon) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Doxifluridine is a second generation nucleoside analog prodrug developed by Roche and used as a cytostatic agent in chemotherapy in several Asian countries including China and South Korea. Doxifluridine is not FDA-approved for use in the USA. It is currently being evaluated in several clinical trials as a stand-alone or combination therapy treatment.   Wikipedia

Chemistry

  • SMILES: C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=C(F)C(=O)NC2=O
  • InChIKey: ZWAOHEXOSAUJHY-ZIYNGMLESA-N
  • Mol. Mass: 246.19
  • ALogP: -1.69
  • ChEMBL Molecule:
    doxifluridine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

5'-deoxy-5-fluorouridine | 5'-deoxy-5'-fluorouridine | 5-dfur | 5'-dfur | 5'-fluoro-5'-deoxyuridine | doxfluridine | doxifluridine | doxyfluridine | flutron | furtulon | ro 21-9738 | uridine-5'-deoxy-5-fluoro-

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Neoplasms ()

Stomach Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue